Agilent Technologies Inc (A) Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

Agilent Technologies Inc (NYSE: A) FY 2026 Other Release

Newsdesk: